European Courts

European Courts 193 European Journal of Health Law 7 : 193-203, 2000. © 2000 Kluwer Law International. Printed in the Netherlands. SELECTED LEGISLATION AND JURISPRUDENCE EUROPEAN COURTS Court of Justice of the European Communities * CJEC 2000/1 Case T-125/96 and T-152/96, Boehringer Ingelheim Vetmedica GmbH and C.H. Boehringer Sohn v. Council Factual background Boehringer produces veterinary medicines containing clenbuterol, a beta- agonist. Beta-agonists are used for therapeutic purposes for both humans and animals. However, beta-agonists are also used as a growth promotor for the artificial fattening of animals. As such, they may entail risks for human health. In 1996, the Council adopted Directive 96/22 aimed at the prohibition of the administration of beta-agonists to food-producing animals, subject to certain clearly defined therapeutic exceptions. This general ban has serious economic implications for Boehringer. For this reason, an application for annulment of the relevant provisions of the directive is addressed to the Court of First Instance. Decision of the Court of First Instance One of the pleas raised by Boehringer to challenge the legality of the directive before the Court of First Instance, concerns the breach of the principle of proportionality. Boehringer accepts that a prohibition of the use of beta- agonists http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png European Journal of Health Law Brill

European Courts

European Journal of Health Law, Volume 7 (2): 193 – Jan 1, 2000

Loading next page...
 
/lp/brill/european-courts-EsMl00XX84
Publisher
Brill
Copyright
© 2000 Koninklijke Brill NV, Leiden, The Netherlands
ISSN
0929-0273
eISSN
1571-8093
D.O.I.
10.1163/15718090020523151
Publisher site
See Article on Publisher Site

Abstract

193 European Journal of Health Law 7 : 193-203, 2000. © 2000 Kluwer Law International. Printed in the Netherlands. SELECTED LEGISLATION AND JURISPRUDENCE EUROPEAN COURTS Court of Justice of the European Communities * CJEC 2000/1 Case T-125/96 and T-152/96, Boehringer Ingelheim Vetmedica GmbH and C.H. Boehringer Sohn v. Council Factual background Boehringer produces veterinary medicines containing clenbuterol, a beta- agonist. Beta-agonists are used for therapeutic purposes for both humans and animals. However, beta-agonists are also used as a growth promotor for the artificial fattening of animals. As such, they may entail risks for human health. In 1996, the Council adopted Directive 96/22 aimed at the prohibition of the administration of beta-agonists to food-producing animals, subject to certain clearly defined therapeutic exceptions. This general ban has serious economic implications for Boehringer. For this reason, an application for annulment of the relevant provisions of the directive is addressed to the Court of First Instance. Decision of the Court of First Instance One of the pleas raised by Boehringer to challenge the legality of the directive before the Court of First Instance, concerns the breach of the principle of proportionality. Boehringer accepts that a prohibition of the use of beta- agonists

Journal

European Journal of Health LawBrill

Published: Jan 1, 2000

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off